Skip to content
Interagency Autism Coordinating Committee (IACC)
Autism Research Database
Office of Autism Research Coordination (OARC)
 
Project Element Element Description

Project Title

Project Title

Double-blind placebo controlled trial of subcutaneous methyl B12 on behavioral and metabolic measures in children with autism 

Principal Investigator

Principal Investigator

Hendren, Robert

Description

Description

Studies have shown that many children with autism exhibit signs of oxidative stress, which causes cellular damage by the presence of highly reactive free radicals. Antioxidants may protect against the damaging effects of oxidative stress, and low antioxidant levels have been observed in children with autism. Nutritional supplementation by injections of the antioxidant methyl B12 is a current alternative medicine treatment for children with autism which has anecdotal reports of clinical improvements. This study will carry out an 8 week, double blind, placebo controlled clinical trial in 50 autistic children aged 3 to 8 years. Researchers will evaluate the subjects' behavioral responses to methyl B12 treatment. Additionally, they will monitor the blood levels of antioxidant metabolites to determine whether methyl B12 treatment can reverse the signs of oxidative stress observed in autism. This study will help determine whether methyl B12 is an effective treatment for core features of autism and may identify novel diagnostic markers for treatment responses in autistic subjects.

Funder

Funder

Autism Speaks

Fiscal Year Funding

Fiscal Year Funding

103536

Current Award Period

Current Award Period

2009-2012

Strategic Plan Question

Strategic Plan Question

Question 4: Which Treatments And Interventions Will Help?

Strategic Plan Objective

Strategic Plan Objective

Yellow dot: Objective has some degree of funding, but less than the recommended amount. 4SC. Test safety and efficacy of at least five widely used interventions (e.g., nutrition, medications, assisted technologies, sensory integration, medical procedures) that have not been rigorously studied for use in ASD by 2012. IACC Recommended Budget: $27,800,000 over 5 years.

Project Link

Project Link

Double-blind placebo controlled trial of subcutaneous methyl B12 on behavioral and metabolic measures in children with autism  (External web link)

Institution

Institution

University of California, Davis

State/Country

State/Country

California

Project Number

Project Number

3031

Federal or Private?

Federal or Private?

Private

Received ARRA Funding?

Received ARRA Funding?

No

History/Related Projects

History/Related Projects

Double-blind placebo controlled trial of subcutaneous methyl B12 on behavioral and metabolic measures in children with autism  | 0 | 2012 | 3031

 
Back to Top